Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 2
Treatment-assignment count: 0
Stratification count: 0
Low Public Signal
EGFR exon 19 deletion
breast cancer · Monoclonal Antibody
EGFR exon 19 deletion is flagged as low public signal because public trials show inclusion required evidence in 4 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT01594177 | https://clinicaltrials.gov/study/NCT00367250 | https://clinicaltrials.gov/study/NCT01688609 | https://clinicaltrials.gov/study/NCT06305962